Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Next Previous
Trial Profile

An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivipansel (Primary)
  • Indications Vaso-occlusive crisis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors GlycoMimetics

    • Most Recent Events

    • 18 Aug 2022 Results assessing efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis from clinical study RESET (NCT02187003) and its OLE (NCT02433158) published in the Blood
    • 07 Dec 2020 Post hoc analyses of the Phase 3 RESET trial and the subsequent pre-planned analysis of the OLE trial published in the GlycoMimetics Media Release.
    • 07 Dec 2020 According to a GlycoMimetics media release, data from this study were presented by by University of California Davis's Theodore Wun at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top